Drug Profile
Ziresovir - Ark Biosciences
Alternative Names: AK-0529; Elsevier; Elsevir®; Exvet; RO-0529Latest Information Update: 01 Jun 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Ark Biosciences
- Class Antivirals; Quinazolines; Small molecules; Thiazepines
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Respiratory syncytial virus infections
- Phase I Unspecified
Most Recent Events
- 24 May 2023 Ark Biosciences plans to launch Ziresovir in China
- 11 Dec 2022 Preregistration for Respiratory syncytial virus infections (In infants) in China (PO)
- 09 Dec 2022 National Medical Products Administration accepts marketing authorization application for Ziresovir in respiratory syncytial virus infection for review